iCardiac Technologies, Inc. (iCardiac Technologies), a patient Monitoring devices company, announced that the company has experienced significant revenue growth as its quarter over quarter revenues have grown in excess of 100%. Additionally, as iCardiac’s revenues have continued to increase, the company achieved profitability in the last quarter of 2008.
Pharmaceutical and biotechnology companies continue to select iCardiac as a critical provider for their cardiac safety studies because of the company’s scientific expertise, project management capabilities, as well as the industry’s most advanced ECG analysis methodologies, which can both dramatically reduce the cost of cardiac safety studies in addition to reducing the likelihood of false-positives.
iCardiac continues to advance the field of cardiac safety in Phase I, II, III as well as TQT studies through its end-to-end offering of cardiac safety analysis services. During 2009, iCardiac will aggressively continue to bring to market its Highly Automated QTsm and QT beat-to-beat offerings.
“To date our highly automated technology has been applied in over 10 clinical QT data analyses,” said Sasha Latypova, executive vice president at iCardiac Technologies. “Pharmaceutical companies are gaining more accurate results and are substantially lowering the cost per Thorough QT study.”
The drive to greater automation of the cardiac safety analysis process stems from general dissatisfaction in the industry regarding “gold standard” manual measurements that are both time-consuming and expensive. iCardiac’s highly automated QT technology is different from “fully automated” approaches – which are based solely on computers – because it combines advanced ECG signal processing algorithms, developed over the past decade, with a robust quality assurance process conducted by cardiologists.
The technology performs a precise automated QT measurement and, using sophisticated statistical models and algorithms, guides cardiologists to those ECGs that require attention. It produces significant cost savings because only a portion of the entire Thorough QT dataset requires manual over-reading.
Automated QT analysis is part of iCardiac’s software platform COMPAS 3.0, originally developed at the University of Rochester Heart Research Follow-Up Program, the international leader in electrophysiology research and the study of the congenital Long QT Syndrome. The platform provides comprehensive analysis of cardiac repolarization signals and contains several advanced arrhythmia biomarkers, as well as advanced ECG signal processing tools. COMPAS serves as the core technology behind the leading cardiac safety analysis services that iCardiac provides to pharmaceutical, biotech companies and clinical research organizations.